AAAAAA

   
Results: 1-25 | 26-50 | 51-65
Results: 1-25/65
THERAPEUTIC TARGETING OF TRANSCRIPTION IN ACUTE PROMYELOCYTIC LEUKEMIA BY USE OF AN INHIBITOR OF HISTONE DEACETYLASE
Authors: WARRELL RP HE LZ RICHON V CALLEJA E PANDOLFI PP
Citation: Rp. Warrell et al., THERAPEUTIC TARGETING OF TRANSCRIPTION IN ACUTE PROMYELOCYTIC LEUKEMIA BY USE OF AN INHIBITOR OF HISTONE DEACETYLASE, Journal of the National Cancer Institute, 90(21), 1998, pp. 1621-1625
WESTERN STUDY OF ARSENIC TRIOXIDE (AS2O3) IN PATIENTS WITH RELAPSED AND OR REFRACTORY ACUTE PROMYELOCYTIC LEUKEMIA/
Authors: SOIGNET SL MASLAK P CHEN YW CALLEJA E PANDOLFI PP SCHEINBERG DA WARRELL RP
Citation: Sl. Soignet et al., WESTERN STUDY OF ARSENIC TRIOXIDE (AS2O3) IN PATIENTS WITH RELAPSED AND OR REFRACTORY ACUTE PROMYELOCYTIC LEUKEMIA/, Annals of oncology, 9, 1998, pp. 675-675
CLINICAL-STUDY OF 9-CIS RETINOIC ACID (LGD1057) IN ACUTE PROMYELOCYTIC LEUKEMIA
Authors: SOIGNET SL BENEDETTI F FLEISCHAUER A PARKER BA TRUGLIA JA CRISP MR WARRELL RP
Citation: Sl. Soignet et al., CLINICAL-STUDY OF 9-CIS RETINOIC ACID (LGD1057) IN ACUTE PROMYELOCYTIC LEUKEMIA, Leukemia, 12(10), 1998, pp. 1518-1521
COMPLETE REMISSION AFTER TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH ARSENIC TRIOXIDE
Authors: SOIGNET SL MASLAK P WANG ZG JHANWAR S CALLEJA E DARDASHTI LJ CORSO D DEBLASIO A GABRILOVE J SCHEINBERG DA PANDOLFI PP WARRELL RP
Citation: Sl. Soignet et al., COMPLETE REMISSION AFTER TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH ARSENIC TRIOXIDE, The New England journal of medicine, 339(19), 1998, pp. 1341-1348
COMPLETE REMISSION AFTER CLINICALLY INDUCED-DIFFERENTIATION AND APOPTOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA BY ARSENIC TRIOXIDE
Authors: SOIGNET SL MASLAK P CHEN YW CALLEJA E PANDOLFI PP SCHEINBERG DA WARRELL RP
Citation: Sl. Soignet et al., COMPLETE REMISSION AFTER CLINICALLY INDUCED-DIFFERENTIATION AND APOPTOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA BY ARSENIC TRIOXIDE, British Journal of Haematology, 102(1), 1998, pp. 225-225
ARSENIC TRIOXIDE AND MELARSOPROL INDUCE PROGRAMMED CELL-DEATH IN MYELOID-LEUKEMIA CELL-LINES AND FUNCTION IN A PML AND PML-RAR-ALPHA INDEPENDENT MANNER
Authors: WANG ZG RIVI R DELVA L KONIG A SCHEINBERG DA GAMBACORTIPASSERINI C GABRILOVE JL WARRELL RP PANDOLFI PP
Citation: Zg. Wang et al., ARSENIC TRIOXIDE AND MELARSOPROL INDUCE PROGRAMMED CELL-DEATH IN MYELOID-LEUKEMIA CELL-LINES AND FUNCTION IN A PML AND PML-RAR-ALPHA INDEPENDENT MANNER, Blood, 92(5), 1998, pp. 1497-1504
PATHOPHYSIOLOGY AND MANAGEMENT OF BONE-DISEASE IN MULTIPLE-MYELOMA
Authors: NIESVIZKY R WARRELL RP
Citation: R. Niesvizky et Rp. Warrell, PATHOPHYSIOLOGY AND MANAGEMENT OF BONE-DISEASE IN MULTIPLE-MYELOMA, Cancer investigation, 15(1), 1997, pp. 85-90
INITIAL CLINICAL-TRIAL OF A SELECTIVE RETINOID-X RECEPTOR-LIGAND, LGD1069
Authors: MILLER VA BENEDETTI FM RIGAS JR VERRET AL PFISTER DG STRAUS D KRIS MG CRISP M HEYMAN R LOEWEN GR TRUGLIA JA WARRELL RP
Citation: Va. Miller et al., INITIAL CLINICAL-TRIAL OF A SELECTIVE RETINOID-X RECEPTOR-LIGAND, LGD1069, Journal of clinical oncology, 15(2), 1997, pp. 790-795
ALL-TRANS-RETINOIC ACID SIGNIFICANTLY INCREASES 5-YEAR SURVIVAL IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA - LONG-TERM FOLLOW-UP OF THE NEW-YORK STUDY
Authors: SOIGNET S FLEISCHAUER A POLYAK T HELLER G WARRELL RP
Citation: S. Soignet et al., ALL-TRANS-RETINOIC ACID SIGNIFICANTLY INCREASES 5-YEAR SURVIVAL IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA - LONG-TERM FOLLOW-UP OF THE NEW-YORK STUDY, Cancer chemotherapy and pharmacology, 40, 1997, pp. 25-29
CLINICAL AND MOLECULAR ASPECTS OF RETINOID THERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA
Authors: WARRELL RP
Citation: Rp. Warrell, CLINICAL AND MOLECULAR ASPECTS OF RETINOID THERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA, International journal of cancer, 70(4), 1997, pp. 496-497
GALLIUM NITRATE FOR THE TREATMENT OF BONE METASTASES
Authors: WARRELL RP
Citation: Rp. Warrell, GALLIUM NITRATE FOR THE TREATMENT OF BONE METASTASES, Cancer, 80(8), 1997, pp. 1680-1685
COMPARATIVE ACTIVITY OF MELARSOPROL AND ARSENIC TRIOXIDE IN CHRONIC B-CELL LEUKEMIA LINES
Authors: KONIG A WRAZEL L WARRELL RP RIVI R PANDOLFI PP JAKUBOWSKI A GABRILOVE JL
Citation: A. Konig et al., COMPARATIVE ACTIVITY OF MELARSOPROL AND ARSENIC TRIOXIDE IN CHRONIC B-CELL LEUKEMIA LINES, Blood, 90(2), 1997, pp. 562-570
THERAPEUTIC TRIALS WITH RETINOIC ACID AND ARSENIC TRIOXIDE (ASO3) IN PML-RAR-ALPHA AND PLZF-RAR-ALPHA TRANSGENIC MICE AS MODELS OF APL
Authors: HE LZ PERUZZI D TRIBIOLI C WARRELL RP PANDOLFI PP
Citation: Lz. He et al., THERAPEUTIC TRIALS WITH RETINOIC ACID AND ARSENIC TRIOXIDE (ASO3) IN PML-RAR-ALPHA AND PLZF-RAR-ALPHA TRANSGENIC MICE AS MODELS OF APL, Blood, 90(10), 1997, pp. 825-825
ARSENIC TRIOXIDE AND MELARSOPROL INDUCE PROGRAMMED CELL-DEATH IN MYELOID-LEUKEMIA CELL-LINES AND FUNCTION IN A PML AND PML RAR-ALPHA INDEPENDENT MANNER/
Authors: WANG ZG RIVI R DELVA L KONIG A SOIGNET S SCHEINBERG D GAMBACORTIPASSERINI C GABRILOVE JL WARRELL RP PANDOLFI PP
Citation: Zg. Wang et al., ARSENIC TRIOXIDE AND MELARSOPROL INDUCE PROGRAMMED CELL-DEATH IN MYELOID-LEUKEMIA CELL-LINES AND FUNCTION IN A PML AND PML RAR-ALPHA INDEPENDENT MANNER/, Blood, 90(10), 1997, pp. 1461-1461
MOLECULAR REMISSION INDUCTION WITHOUT RELAPSE AFTER ANTI-CD33 MONOCLONAL-ANTIBODY HUM195 IN ACUTE PROMYELOCYTIC LEUKEMIA (APL)
Authors: JURCIC JG DEBLASIO A DUMONT L WARRELL RP SCHEINBERG DA
Citation: Jg. Jurcic et al., MOLECULAR REMISSION INDUCTION WITHOUT RELAPSE AFTER ANTI-CD33 MONOCLONAL-ANTIBODY HUM195 IN ACUTE PROMYELOCYTIC LEUKEMIA (APL), Blood, 90(10), 1997, pp. 1850-1850
MELARSOPROL, AN ORGANIC ARSENICAL, IN THE TREATMENT OF REFRACTORY LEUKEMIA - LABORATORY AND CLINICAL-RESULTS
Authors: SOIGNET SL RIVI R KONIG A TONG WP GABRILOVE J SCHEINBERG DA PANDOLFI PP WARRELL RP
Citation: Sl. Soignet et al., MELARSOPROL, AN ORGANIC ARSENICAL, IN THE TREATMENT OF REFRACTORY LEUKEMIA - LABORATORY AND CLINICAL-RESULTS, Blood, 90(10), 1997, pp. 2258-2258
INITIAL CLINICAL-TRIAL OF THE RETINOID RECEPTOR PAN AGONIST 9-CIS RETINOIC ACID
Authors: MILLER VA RIGAS JR BENEDETTI FM VERRET AL TONG WP KRIS MG GILL GM LOEWEN GR TRUGLIA JA ULM EH WARRELL RP
Citation: Va. Miller et al., INITIAL CLINICAL-TRIAL OF THE RETINOID RECEPTOR PAN AGONIST 9-CIS RETINOIC ACID, Clinical cancer research, 2(3), 1996, pp. 471-475
ACUTE-RENAL-FAILURE ASSOCIATED WITH THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA
Authors: FLOMBAUM CD ISAACS M REICH L BERMAN E WARRELL RP
Citation: Cd. Flombaum et al., ACUTE-RENAL-FAILURE ASSOCIATED WITH THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA, American journal of kidney diseases, 27(1), 1996, pp. 134-137
PATHOGENESIS IS AND MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA
Authors: WARRELL RP
Citation: Rp. Warrell, PATHOGENESIS IS AND MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA, Annual review of medicine, 47, 1996, pp. 555-565
METABOLIC PHENOTYPES OF RETINOIC ACID AND THE RISK OF LUNG-CANCER
Authors: RIGAS JR MILLER VA ZHANG ZF KLIMSTRA DS TONG WP KRIS MG WARRELL RP
Citation: Jr. Rigas et al., METABOLIC PHENOTYPES OF RETINOIC ACID AND THE RISK OF LUNG-CANCER, Cancer research, 56(12), 1996, pp. 2692-2696
ORGANIC ARSENICAL MELARSOPROL SHOWS GROWTH SUPPRESSIVE ACTIVITY VIA PROGRAMMED CELL-DEATH ON APL AND OTHER MYELOID AND LYMPHOID LEUKEMIA-DERIVED CELL-LINES
Authors: RIVI R CALLEJA E KONIG A LAI L GAMBACORTIPASSERINI C SCHEINBERG D GABRILOVE JL WARRELL RP PANDOLFI PP
Citation: R. Rivi et al., ORGANIC ARSENICAL MELARSOPROL SHOWS GROWTH SUPPRESSIVE ACTIVITY VIA PROGRAMMED CELL-DEATH ON APL AND OTHER MYELOID AND LYMPHOID LEUKEMIA-DERIVED CELL-LINES, Blood, 88(10), 1996, pp. 260-260
INITIAL CLINICAL-STUDY OF A NOVEL ORGANIC ARSENICAL, MELARSOPROL, IN PATIENTS WITH ADVANCED LEUKEMIA
Authors: SOIGNET S TONG WP GABRILOVE J SCHEINBERG DA PANDOLFI PP WARRELL RP
Citation: S. Soignet et al., INITIAL CLINICAL-STUDY OF A NOVEL ORGANIC ARSENICAL, MELARSOPROL, IN PATIENTS WITH ADVANCED LEUKEMIA, Blood, 88(10), 1996, pp. 865-865
HIGHLY SENSITIVE RT-PCR ASSAY FOR DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA
Authors: PERUZZI D DEBLASIO T WARRELL RP PANDOLFI PP
Citation: D. Peruzzi et al., HIGHLY SENSITIVE RT-PCR ASSAY FOR DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA, Blood, 88(10), 1996, pp. 1452-1452
IN-VITRO EFFECTS OF MELARSOPROL AS COMPARED TO ARSENIC TRIOXIDE (AS2O3) IN CHRONIC LYMPHOID MALIGNANCIES
Authors: KONIG A WRAZEL L WARRELL RP PANDOLFI PP RIVI R ALKATIB A GABRILOVE JL
Citation: A. Konig et al., IN-VITRO EFFECTS OF MELARSOPROL AS COMPARED TO ARSENIC TRIOXIDE (AS2O3) IN CHRONIC LYMPHOID MALIGNANCIES, Blood, 88(10), 1996, pp. 2352-2352
PROGNOSTIC-SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTION AND PMLRAR-ALPHA ISOFORM TYPE - LONG-TERM FOLLOW-UP IN ACUTE PROMYELOCYTIC LEUKEMIA (APL)/
Authors: JURCIC JG MILLER WH DEBLASIO A SCHEINBERG DA WARRELL RP
Citation: Jg. Jurcic et al., PROGNOSTIC-SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTION AND PMLRAR-ALPHA ISOFORM TYPE - LONG-TERM FOLLOW-UP IN ACUTE PROMYELOCYTIC LEUKEMIA (APL)/, Blood, 88(10), 1996, pp. 2529-2529
Risultati: 1-25 | 26-50 | 51-65